Entrada Therapeutics
Boston · Founded 2016
About Entrada Therapeutics
Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $301.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2024)
- Ticker: nasdaq:TRDA
- Website: entradatx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Emergency Medicine, Genetics, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/entrada-therapeutics-24127 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.